New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
07:56 EDTLLY, ARIAARIAD volatility may move, Eli Lilly approached Daily Mail says
ARIAD (ARIA) option implied volatility could pick up after the U.K.'s Daily Mail said the company has been approached by Eli Lilly (LLY) regarding a possible deal, with Lilly reportedly willing to pay up to $20 per share cash for Ariad. Overall option implied volatility of 85 is below its 26-week average of 90 according to Track Data, suggesting decreasing price movement.
News For ARIA;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
10:56 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
February 24, 2015
10:12 EDTARIAOptions with increasing implied volatility: LO ARIA OWW
06:34 EDTLLYEli Lilly CEO states company is not for sale, Financial Times says
Subscribe for More Information
February 23, 2015
10:45 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
08:31 EDTLLYEli Lilly announces delay in submission of basal insulin peglispro beyond Q1
Subscribe for More Information
07:06 EDTLLYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information
05:46 EDTARIAStocks with implied volatility movement; ARIA CYBR
Subscribe for More Information
February 20, 2015
06:35 EDTARIASarissa Capital seeks retirement of ARIAD CEO, board seats
Sarissa Capital disclosed in a regulatory filing that it has been in negotiations with members of ARIAD's board in an attempt to avoid a potential proxy contest. Sarissa said it indicated its belief that the board undertake measures to effect and facilitate the imminent retirement of Harvey Berger as CEO and that any settlement of a potential proxy contest must include the CEO’s retirement. It added that no settlement has been reached. Sarissa believes the board "as currently constructed is not up to the task of providing the stewardship necessary to optimally navigate" the company. On February 19, Sarissa notified ARIAD that it intends to appear at the company's 2015 annual meeting of stockholders to nominate and seek to elect Richard Mulligan, Ph.D. and Anna Protopapas to the eight member staggered board of directors. Sarissa intends to seek to unseat Harvey Berger, ARIAD's Chairman and CEO, and Wayne Wilson, the lead independent director, with its two nominees. Sarissa added that it is "extremely concerned" with the conduct of certain members of the board, "particularly with respect to compensation, governance and financial matters." The hedge fund said it may ultimately initiate court proceedings to seek to remove one or more directors for cause based on potential breaches of their fiduciary duties. Sarissa Capital has a 6.9% stake in ARIAD.
February 19, 2015
08:04 EDTLLYEli Lilly extends Evacetrapib Phase 3 trial by six months
Subscribe for More Information
07:39 EDTARIAARIAD expects to file IND application for AP32788 this year
ARIAD says "We expect to file an investigational new drug application for AP32788 this year and to begin a Phase 1/2 proof-of-concept trial in 2016. This will be our third IND filing of an internally discovered oncology development candidate in the past eight years." The company also says "We anticipate presenting updates from the ongoing Phase 1/2 clinical trial of brigatinib at the 2015 European Lung Cancer Conference and the American Society of Clinical Oncology meetings later this year. Additionally, we expect to present preliminary data from the brigatinib ALTA trial in the second half of 2015."
07:38 EDTARIAARIAD sees FY15 net product revenues from sales of Iclusig $130M-$140M
Net product revenues from sales of Iclusig are expected to be in the range of $130M-$140M. This guidance includes sales of Iclusig in the U.S., Europe, and other select countries where ARIAD has distributorships in place. R&D expenses are expected to be in the range of $185M-$195M, reflecting increased development activities for Iclusig, brigatinib, and AP32788, as well as ongoing discovery research efforts. Expenses related to Iclusig represent approximately 50% of total R&D expenses and include the three new planned trials to begin this year, as well as all ongoing trials. Expenses related to brigatinib represent approximately 35% of total R&D expenses and include the two ongoing trials and NDA-enabling pre-clinical studies.
07:37 EDTARIAARIAD reports Q4 EPS (3c), consensus (20c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use